tiprankstipranks
Trending News
More News >
Adverum Biotechnologies (ADVM)
:ADVM
Advertisement

Adverum Biotechnologies (ADVM) AI Stock Analysis

Compare
631 Followers

Top Page

ADVM

Adverum Biotechnologies

(NASDAQ:ADVM)

Rating:44Neutral
Price Target:
$2.50
▼(-7.41%Downside)
Adverum Biotechnologies' overall stock score is primarily impacted by its weak financial performance and concerning valuation metrics. Although technical analysis shows some short-term strength, the long-term outlook remains weak. The absence of earnings call data and corporate events further limits the positive factors influencing the score.
Positive Factors
Clinical Trials
Patient enrollment for ARTEMIS, the first P3 study for ixo-vec, is ahead of schedule, indicating strong interest and potential success in the clinical trial.
Efficacy and Safety
Ixo-vec has demonstrated paradigm shifting potential in the treatment of neovascular or wet AMD patients with its differentiated injection durability profile, and safety and tolerability with reliable inflammation management.
Funding and Financial Strategy
The $125.7M in cash and equivalents is anticipated to fund operations into the second half of 2025, supporting the ongoing pivotal program.
Negative Factors
Clinical Trial Dependency
The second P3 study, AQUARIUS, won't start until financing is secured, creating a dependency on new funding to progress.
Financing Needs
Given very limited cash and the need for a second pivotal P3 study for ixo-vec, a near-term announcement on meaningful financing or a significant partnership is critical.
Liquidity Challenges
Partnership discussions are still active, with significant business development interest, despite current liquidity challenges.

Adverum Biotechnologies (ADVM) vs. SPDR S&P 500 ETF (SPY)

Adverum Biotechnologies Business Overview & Revenue Model

Company DescriptionAdverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
How the Company Makes MoneyAdverum Biotechnologies generates revenue primarily through collaboration and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestones, and royalties based on the successful development and commercialization of product candidates. Additionally, Adverum may receive funding from grants and research contracts to advance its gene therapy programs. The company's earnings are influenced significantly by the progress of its clinical trials and the potential market approval of its therapies.

Adverum Biotechnologies Financial Statement Overview

Summary
Adverum Biotechnologies is facing significant financial challenges. The income statement shows ongoing operational losses, the balance sheet indicates increasing leverage and a shrinking equity base, and cash flows are consistently negative, highlighting liquidity risks and the need for operational improvements.
Income Statement
35
Negative
Adverum Biotechnologies has experienced significant challenges in its income statement. The company reported negative EBIT and net income for several years, indicating ongoing operational losses. The gross profit margin fluctuates with occasional positive figures, but the net profit margin remains negative, highlighting profitability issues. Revenue growth is erratic with periods of no revenue, showing instability in generating consistent revenue streams.
Balance Sheet
45
Neutral
The balance sheet of Adverum Biotechnologies reveals a moderately leveraged position with a debt-to-equity ratio that suggests manageable debt levels relative to its equity. However, the company's equity has decreased over time, reflecting a reduction in financial stability. The equity ratio shows a decline, indicating that liabilities are becoming a larger portion of the company's financial structure, potentially increasing financial risk.
Cash Flow
40
Negative
Adverum Biotechnologies faces challenges in cash flow management. Operating cash flow has been consistently negative, which signifies operational struggles to generate cash. Free cash flow remains negative, indicating heavy cash outflows relative to inflows. Despite occasional financing inflows boosting cash reserves, the reliance on external financing could indicate potential liquidity risks without operational improvements.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.00M3.60M0.007.50M0.00
Gross Profit-2.65M-2.04M-6.53M2.85M-4.16M
EBITDA-127.27M-123.30M-147.93M-140.90M-112.23M
Net Income-130.93M-117.17M-154.54M-145.54M-117.51M
Balance Sheet
Total Assets179.84M173.01M308.37M439.73M482.57M
Cash, Cash Equivalents and Short-Term Investments125.69M96.53M185.59M305.19M429.73M
Total Debt91.70M75.04M106.80M102.99M30.71M
Total Liabilities109.13M89.54M126.85M123.54M48.22M
Stockholders Equity70.71M83.47M181.52M316.19M434.35M
Cash Flow
Free Cash Flow-92.85M-91.71M-119.91M-122.95M-91.14M
Operating Cash Flow-92.46M-90.90M-108.09M-107.83M-79.29M
Investing Cash Flow-41.89M96.88M141.72M78.71M-280.17M
Financing Cash Flow120.00M69.00K607.00K2.40M355.99M

Adverum Biotechnologies Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.70
Price Trends
50DMA
2.45
Positive
100DMA
3.19
Negative
200DMA
4.51
Negative
Market Momentum
MACD
0.07
Negative
RSI
54.48
Neutral
STOCH
43.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADVM, the sentiment is Neutral. The current price of 2.7 is above the 20-day moving average (MA) of 2.53, above the 50-day MA of 2.45, and below the 200-day MA of 4.51, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 54.48 is Neutral, neither overbought nor oversold. The STOCH value of 43.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ADVM.

Adverum Biotechnologies Risk Analysis

Adverum Biotechnologies disclosed 71 risk factors in its most recent earnings report. Adverum Biotechnologies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Adverum Biotechnologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.62B0.05-63.03%2.44%16.33%0.31%
52
Neutral
$105.26M-78.93%-70.15%
46
Neutral
$76.95M-245.59%27.36%23.82%
44
Neutral
$90.77M-55.14%-99.43%-69.40%
44
Neutral
$55.78M-127.99%37.54%
30
Underperform
$156.93M-744.59%27.65%
$54.24M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ADVM
Adverum Biotechnologies
2.70
-5.39
-66.63%
IGMS
IGM Biosciences
1.28
-10.82
-89.42%
ELTX
Elicio Therapeutics
9.81
4.91
100.20%
ADAG
Adagene
1.99
-0.54
-21.34%
TCRX
TScan Therapeutics
1.87
-5.31
-73.96%
ANL
Adlai Nortye Ltd. Sponsored ADR
1.47
-1.98
-57.39%

Adverum Biotechnologies Corporate Events

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Adverum Biotechnologies Holds Annual Meeting with Key Votes
Neutral
Jun 18, 2025

On June 17, 2025, Adverum Biotechnologies held its Annual Meeting, where stockholders voted on several key proposals. The election of Class II directors, ratification of Ernst & Young LLP as the independent accounting firm, and approval of executive compensation were among the decisions made. Additionally, stockholders approved amendments to the 2024 Equity Incentive Award Plan and the reduction of exercise prices for certain stock options, reflecting strategic adjustments to enhance shareholder value.

The most recent analyst rating on (ADVM) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Adverum Biotechnologies stock, see the ADVM Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025